ust as speculation dwindled about the odds of Teva Pharmaceutical Industries Ltd. making a play for generic drug maker Mylan Inc., the Jerusalem-based pharma giant made known its plan to enliven the pipeline by way of a different deal: a $3.2 billion tender offer for all of orphan-drug firm Auspex Pharmaceuticals Inc.'s outstanding shares at $101 each. Read More
Horizon Pharma plc is looking to add approved drugs Ravicti (glycerol phenylbutyrate) and Buphenyl (sodium phenylbutyrate) to its orphan drug business by acquiring the outstanding shares of developer Hyperion Therapeutics Inc. for $46 apiece in cash, or approximately $1.1 billion. Read More
There is no doubt that the field of cancer immunotherapy is attracting a great deal of attention from investors and big pharma companies alike these days. With plenty of deals being racked up in this space, Berkeley, Calif.-based Aduro Biotech Inc. is the latest company to forge a major collaboration based on immuno-oncology research. Read More
A failure of Can-Fite Biopharma Ltd.'s lead candidate to achieve what the company called "any real effect" over placebo in patients with moderate-to-severe plaque psoriasis sent shares (NYSE:CANF) tumbling more that 60 percent to a 52-week low on Monday before closing at $2.20. Read More
A much-hyped January alliance with the MD Anderson Cancer Center bringing together a suite of technologies in the red hot CAR T-cell space caught the attention of Merck Serono, which inked a potential $941 million deal with Intrexon Corp. Read More
LONDON – The UK's 100,000 Genomes Project has brought together a consortium of 10 pharma and biotech companies to begin work on translating whole genome sequence information from rare diseases and cancer patients into drugs and diagnostics. Read More
While the patent challenge that's delaying the launch of the first biosimilar approved in the U.S. is grabbing headlines, some lawmakers may be second-guessing the final act of the Biologics Price Competition and Innovation Act (BPCIA). Read More
SHANGHAI – China's Ebola vaccine, Ad5-EBOL, is setting a new standard for technological capability and speed having generated strong phase I immunogenicity and safety data in Chinese patients within just three months. Read More
strong>Spectral Medical Inc., of Toronto, said in connection with the previously announced offering to Toray Industries Inc. of 9,041,592 common shares at C$0.553 per share, Birch Hill Equity Partners IV LP, Birch Hill Equity Partners (US) IV, LP, and Birch Hill Equity Partners (Entrepreneurs) IV, LP have exercised their anti-dilution rights to acquire 2,007,872 shares for net proceeds of C$1,110,353. Read More
Bioblast Pharma Ltd., of Tel Aviv, Israel, presented positive in vivo proof-of-concept Cabaletta data in spinocerebellar ataxia type 3 (SCA3), or Machado Joseph disease, at the International Ataxia Research Conference held last week in Windsor, UK. Read More
Lion Biotechnologies Inc., of Los Angeles, said researchers from Moffitt Cancer Center reported results from a pilot trial of tumor infiltrating lymphocytes (TIL) and Yervoy (ipilimumab, Bristol-Myers Squibb Co.) in patients with metastatic melanoma at the Society of Surgical Oncology 2015 meeting in Houston. Read More
Fujifilm Holdings Corp., of Tokyo, plans to acquire Cellular Dynamics International Inc. (CDI), of Madison, Wis., via an all-cash tender offer, followed by a second step merger. Fujifilm will acquire CDI's outstanding shares for $16.50 per share, or approximately $307 million on a fully diluted basis, representing a premium of 108 percent to CDI's closing price of $7.94 on March 27. Read More
Janssen Research & Development LLC, of Titusville, N.J., part of Johnson & Johnson, said three-month paliperidone palmitate (Invega Sustenna), its atypical antipsychotic candidate, significantly delayed time to relapse compared to placebo in patients with schizophrenia, according to phase III findings published in the Journal of the American Medical Association Psychiatry. Read More
